Deep Tech Startups

Occam Razor develops drug discovery technology using digital science to target neurodegenerative diseases, focusing initially on Parkinson's disease and brain aging.

4 investors

1910 Genetics develops genetic engineering and biotechnology solutions, leveraging computational and biological approaches. The company serves the biotech and life sciences industry.

4 investors

2D Photonics develops graphene-integrated photonics technology for optical transceivers and interconnects used in data-intensive applications such as generative AI workloads. Its architecture aims to deliver high bandwidth density, wavelength-independent operation, and low power consumption while remaining compatible with silicon foundry manufacturing.

4 investors

3DOS is a peer-to-peer 3D printing and manufacturing network that enables users to upload designs, earn royalties, and produce products on demand globally. The platform connects designers, brands, and creators with a distributed network of 3D printer owners for decentralized manufacturing.

4 investors

8i develops virtual and augmented reality technologies for human connection and immersive experiences, serving audiences across entertainment, education, training, and professional settings.

4 investors

Adept Materials develops a moisture-control material technology that provides directional vapor control, humidity regulation, and temperature management, applied as coatings, films, and overlays. Spun out of a Brown University physics lab, its technology targets buildings, apparel, packaging, and healthcare applications with a focus on durability and energy efficiency.

4 investors

AgileRL offers Arena, a platform that unifies training, tuning, and deployment of reinforcement learning models, with built-in evolutionary hyperparameter optimization and distributed multi-GPU training for single- and multi-agent tasks. It provides an open-source Python-first framework serving research labs and teams in defense, finance, robotics, and logistics, supporting on/off-policy, offline RL, bandit, and LLM fine-tuning workflows.

4 investors

aiMotive develops tooling and embedded software for automated driving, including simulation (aiSim), data management (aiData), and perception (SVNet) products used by automotive partners to build ADAS and autonomous driving systems. It supplies these solutions to carmakers and suppliers, notably supporting Stellantis's STLA AutoDrive platform.

4 investors

Aira Technology applies AI to help mobile network operators modernize their existing Radio Access Network (RAN), enabling gains in spectrum, energy, and operating cost efficiency. It offers AI-defined cellular network technology and works with operators through partnerships and demos.

4 investors

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.

4 investors

Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

4 investors

Algorithmiq develops quantum algorithms that combine classical and quantum computers to solve problems in chemistry and life sciences, with a focus on drug discovery and development for rare diseases. Its products include a quantum computer interface and proprietary quantum chemistry algorithms applicable to materials, drugs, and energy.

4 investors

Alloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

4 investors

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

4 investors

Althea provides a payment layer and a hybrid EVM blockchain built for infrastructure and connectivity, and since 2018 has delivered blockchain-enabled internet access to homes across varied terrain. Its Liquid Infrastructure product lets users fund and tokenize networked utilities such as fiber optic cable and cell tower capacity.

4 investors

Altrove uses physics-based AI and lab automation to design and manufacture substitutes for critical inorganic materials, aiming to develop alternatives faster than conventional R&D. It targets global industrials seeking to replace critical materials that pose supply chain, cost, and regulatory risks.

4 investors

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

4 investors

Anadyr Horizon builds predictive simulation software powered by what it calls Agentic Systems Intelligence (ASI), designed to model human decisions and strategic outcomes before they occur. Originating from a security simulation program at Harvard, the company positions its product as decision infrastructure for strategic foresight and escalation prediction.

4 investors

Anara is an AI platform designed for scientific research that searches document libraries and the web, summarizes findings with automatic citations, and helps researchers write with verified sources. It specializes in document analysis and synthesis for scientific and life science workflows.

4 investors

Animab is a biotechnology company developing oral antibody-based products that target intestinal pathogens to improve gut health in livestock, with a focus on protecting piglets during the post-weaning stage. Its technology integrates antibodies directly into animal feed to prevent bacterial colonization, reducing infections and antimicrobial use.

4 investors

Answer.AI is an AI research and development lab that turns foundational research into practical end-user products, including open-source tools and models such as ModernBERT and the Solveit coding/education product. Its work spans AI research, retrieval methods, and developer tooling.

4 investors

Antarka develops a skin-permeable enzyme derived from Antarctic organisms that repairs UV-induced DNA damage, offered as a high-purity active ingredient for cosmetic brands to formulate into anti-aging creams, sunscreens, and repair serums. The company operates in the biotech and dermocosmetics space, supplying formulators rather than selling finished consumer products directly.

4 investors

Anthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.

4 investors

Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications. The company builds deep-tech solutions for ocean exploration and resource management.

4 investors